Kristi Panchuk, MN, NP(Family) (a), M. Judith Lynam, RN, PhD (a)
(a) School of Nursing, University of British Columbia, Vancouver, BC
Polycystic ovary syndrome (PCOS) is a common, complex endocrinopathy with lifelong implications for patients and their families. The genetic and environmental etiologies of PCOS are not yet fully understood, (1) but one hypothesis is that genetic factors promote fetal androgen secretion and this predisposes certain females to hyperandrogenism, oligo-ovulation or anovulation, with an associated increase in the number of follicles in the ovary. (2) The prevalence of the disease is commonly cited as affecting four to seven percent of women of reproductive age, (3) though estimates based on diagnostic criteria that include ultrasound are as high as 17.8%.4 It is particularly concerning that 69% of women who met diagnostic criteria for PCOS in this study were undiagnosed. (4) As a consequence of undiagnosed disease, many women are living with unmonitored and unmanaged physical, psychological, and social challenges. Evidence strongly suggests that in addition to their presenting complaints during their reproductive age, women with PCOS have significant health risks including obesity, the metabolic syndrome (METS), type 2 diabetes mellitus (T2DM), and certain cardiovascular risk factors. (5) The high prevalence of the disease means identifying women with PCOS and managing their risks proactively across the lifespan will potentially prevent or mitigate the consequences of this chronic disease.
THE DIAGNOSTIC CHALLENGE: A SINGLE PROFILE OR MULTIPLE PHENOTYPES?
In the last ten years, two consensus groups have revised diagnostic criteria and highlighted health risks associated with PCOS. Since PCOS is a syndrome with elements common to other disorders (including thyroid dysfunction, hyperprolactinemia, non-classical adrenal hyperplasia, and Cushing’s syndrome), it is a diagnosis of exclusion in the presence of two of the following three criteria: oligo– or anovulation, clinical and/ or biochemical hyperandrogenism, and polycystic ovaries on ultrasound. According to the Rotterdam Consensus Group, any two of these three criteria are adequate for diagnosis. (6) The inclusion of ultrasound criteria (presence of 12 or more follicles and/or increased ovarian volume) is significant because prior to 2003, the diagnosis was based on the presence of two criteria, to the exclusion of other etiologies: chronic anovulation and hyperandrogenism. As a result of including the ultrasound criteria, there are four possible phenotypes of women who could receive the diagnosis of PCOS: women with all three criteria, women with hyperandrogenism and oligo– or anovulation, women with hyperandrogenism and polycystic ovaries, and women with oligo– or anovulation and polycystic ovaries. In an extensive review of the Rotterdam criteria, Geisthövel argued that these criteria may prompt over-diagnosis because the criteria are vaguely defined. (7) He proposed using androgenization as the criterion for diagnosing the condition and distinguishing between phenotypes. The phenotypic diversity also presents clinical challenges because women with the same diagnosis may represent different risk profiles.
The most recent consensus group, formed by the Androgen Excess and PCOS Society, concluded that hyperandrogenism is a necessary criterion for diagnosis, in addition to at least one of oligo-anovulation or polycystic ovarian morphology. (8) Under these criteria women with the milder phenotype of polycystic ovaries and oligo– or anovulation are not diagnosed as having PCOS. Significant endocrine abnormalities and increased body mass index and waist circumference are characteristic of women with phenotypes including androgen excess and oligo-anovulation, with only milder abnormalities evident in the phenotypes with only polycystic ovaries and either androgen excess or oligo-anovulation. (9) The risk of cardiovascular disease is increased in the hyperandrogenic phenotypes of PCOS,5 however, this risk is yet to be confirmed in normoandrogenic phenotypes. PCOS patients lacking androgenic variations are at lower risk for metabolic syndrome and insulin insensitivity. (10) These early insights about the characteristics of the main phenotypes demonstrate that women with PCOS are a complex population who could require different approaches to management.
Even with consensus guidelines, achieving an accurate diagnosis is challenging for clinicians because of variability in ultrasound evaluation, unreliability of serum androgen levels, subjectivity in measuring hirsutism, and inaccuracy in timing serum progesterone testing. (11) Lujan et al. conclude that a conservative approach to diagnosis (for instance, including androgen excess as an essential criterion) will promote research and intervention to improve care of women with PCOS. (11) Yet, these authors support the Rotterdam criteria because these criteria include the widest phenotypic variation. This tension can be attenuated with a clinical emphasis on identifying women with androgen excess as accurately as possible with current diagnostic capabilities, while researchers explore strategies for improving diagnostic investigations and clarify the variation in health risks among phenotypes. Until diagnostic standards and the related clinical implications are determined, managing lowerrisk phenotypes should be a dynamic process of responding to individual needs in light of emerging research.
RECOGNIZING AND APPRECIATING THE IMPACT OF PCOS
As a syndrome, PCOS has multiple characteristics derived from common mechanisms. (12) The following discussion highlights some common clinical manifestations and complications of PCOS. Hyperandrogenism is the most consistently emphasized diagnostic feature of PCOS, and manifests clinically or as elevated serum androgen levels. Hirsutism is the most common clinical manifestation of hyperandrogenism, and can be experienced by adolescent and adult women with PCOS, affecting 50-76% of women with the diagnosis. (13) Adult acne or severe adolescent acne is also evidence of hyperandrogenism and affects 10-34% of PCOS patients. (13) The second diagnostic feature central to PCOS is ovulatory dysfunction, which commonly (though not exclusively) manifests as menstrual irregularity or the absence of menses.
Impact of PCOS on health status
Though not all women with PCOS are overweight or obese, the average body mass index (BMI) of women with PCOS is higher than normal, and obesity is common in women with PCOS. (3) There is evidence that PCOS influences women’s metabolic activity in cases of normal and high BMI. For instance, women of normal weight with PCOS consume an average of about 400 kilocalories less than women of normal weight without PCOS despite no significant difference in physical activity. (14) Women of normal weight with PCOS also report difficulty maintaining their weight. (15) The relationship between obesity and PCOS is complex in that adipocytes in women with PCOS behave differently than those of women without PCOS with regard to appetite regulation and steroid hormone metabolism. Obesity worsens the PCOS phenotype, and hyperandrogenemia contributes to central (android) obesity, which worsens insulin resistance. (16-19) Strategies for weight management that are broadly applied to people who are overweight or obese may need to be adjusted for women with PCOS as their metabolic environment is influenced by their disease.
Type 2 diabetes mellitus
Insulin resistance and impaired glucose tolerance (IGT) are precursors to T2DM. An estimated 40% to 58% of women with PCOS have insulin resistance, (19) in contrast to 7.2% of lean women without PCOS.20 IGT and T2DM may be present in 9.4% and 1.6% of women with PCOS respectively. (20) Other researchers found 10% of adolescents and 20% of adult PCOS patients have IGT, irrespective of BMI. (21) Women with PCOS have a high rate of conversion from IGT to T2DM, (22) and have a relative risk of 4.0-6.0 of developing diabetes. PCOS patients contribute 15% to 36% of the overall disease burden of T2DM in white women, which is consistent with the number of women with T2DM with undiagnosed PCOS. (23) Oligomenorrhea presents a 2-2.5 times greater risk of T2DM, regardless of PCOS diagnosis,24 which points to a relationship between menstrual irregularities and systemic complications.
Insulin resistance has a number of systemic effects that increase the risk of cardiovascular events and T2DM, and these effects together comprise the metabolic syndrome (METS). In addition to diagnostic criteria for PCOS, the 2003 consensus group defined criteria for METS in women with PCOS to include at least three of the following: waist circumference >88 cm (35 in), triglycerides ≥150 mg/dL, HDL-C <50 mg/dL, systolic blood pressure ≥130 or diastolic blood pressure ≥85, and fasting glucose 100-126 mg/ dL or a glucose tolerance test with a 2-h glucose 140-199 mg/ dL.6 Recent analyses suggest that the prevalence of METS is on the rise among women of childbearing age. (25) METS has up to a 46% prevalence rate in adults and adolescents with PCOS and is more common in women under 30 years old. (26,27) Stress is one possible explanation for the correlation between PCOS and METS. (28) Women with a family history of T2DM, obesity, and elevated fasting insulin levels are more likely to manifest more components of METS. (27)
Lipid abnormalities and cardiovascular risk
Elevated triglycerides and reduced high-density lipoprotein levels, which are exacerbated by obesity, are among the components of METS that are cardiovascular risk factors. As part of METS, lipid variances are common to women with PCOS regardless of BMI. (29) In addition, there are well–documented variations in markers of atherosclerosis, such as increased carotid intima-media thickness and coronary artery calcification. (5) Research is wanting in terms of cardiac events, in part because of the lack of clarity around the risks associated with each of the phenotypes of PCOS. (30) One research group calculated that the risk of myocardial infarction increases four– to seven-fold in women with PCOS. (24) Multifactorial risk for cardiovascular disease in women with PCOS warrants careful consideration of screening practices and preventive management.
Gynecologic and obstetric complications
Infertility is a common presenting complaint for women with PCOS. Women who meet the waist circumference criteria for METS (greater than 88 cm) and have a BMI greater than (30) have a 50% reduced likelihood of spontaneous conception, (22) regardless of their PCOS status. When obesity is combined with the irregularly ovulatory or anovulatory states typical of PCOS, the chance of conception is likely lower. Pregnancy is also associated with increased risks for obese women, who are at risk for gestational diabetes and hypertension during pregnancy and their children are at risk for congenital anomalies, including cardiac defects. (22) Recurrent miscarriage is more common in women who are obese, however, there is no conclusive evidence for this association. (31) In one study, 56% of women with recurrent miscarriage also had PCOS, and although this is a higher prevalence than the normal population, the authors concluded that PCOS was not an independent etiological factor for recurrent miscarriage. (32)
Further reproductive health outcomes for women with PCOS include increased rates of hysterectomy (odds ratio of 4:1), usually for benign reasons like fibroids or persistent vaginal bleeding. (33) Given infrequent shedding of the endometrium in oligo– or anovulatory women, the risk of endometrial cancer is increased in women with PCOS, though the precise risk has not been defined. (34) Clinicians should therefore maintain a low threshold for recommending endometrial biopsy in these women because they are at increased risk for hyperplasia and carcinoma.
Mental health issues and quality of life
PCOS frequently manifests itself at puberty or during young adulthood with features like hirsutism and obesity, which affect self-image, self-esteem, and quality of life of young women. (35) Women with PCOS experience psychopathology more often than women without PCOS. More than half of women with PCOS have anxiety on clinical assessment, and this anxiety is often undiagnosed. (36) Over 60% of women with PCOS have depressive disorders, but again, there is insufficient evidence as of yet to determine phenotypic variations. (37) Eating disorders affect 35% of women with hirsutism, many of whom have PCOS. (38) Obesity is closely associated with eating disorders, and eating disorders are ten times more common in hirsute patients than in the general population. (38) One explanation for the 16% of PCOS women with bulimia is that androgens stimulate appetite and decrease impulse control, so the circulating levels of these hormones promote inappropriate eating behaviours. (39)
In addition to being over-represented in populations with psychiatric illness, women with PCOS rate their quality of life lower than not only healthy women, but in the psychological aspect, quality of life scores are 20% lower than people with many other chronic diseases like asthma, epilepsy, diabetes, and coronary heart disease. (15) Among adolescents with PCOS, lower scores on quality of life indicators seem to correlate with increased BMI, (40) but in adult women with PCOS, the reduced quality of life is independent of BMI. (35)
RESPONDING TO WOMEN WITH PCOS
Presenting to a clinician with sub-fertility is the only time in their lives when many women receive care for PCOS. This means women who meet diagnostic criteria for PCOS but delay childbearing, never attempt to conceive, or have no difficulty conceiving are unlikely to receive a diagnosis or management for PCOS. Clinicians should be alert to the variety of issues with which women with PCOS may initially present and maintain a low threshold for performing comprehensive clinical assessment to identify or rule out PCOS.
Goals and challenges of clinical management
The overall goals of care for women with PCOS are to promote regular menses, ovulation, and fertility, while reducing cardiovascular risk, effects of insulin resistance, hirsutism and acne, risk of endometrial carcinoma, and incidence of T2DM. (41,42) Diagnosing PCOS in adolescence and offering early treatment may mitigate the effects of hyperandrogenemia on the hypothalamus and slow the evolution of PCOS, (43) and at the very least delay or prevent serious consequences: psychopathology, T2DM, and cardiovascular risks. Educating women about PCOS and management strategies is in itself an intervention that may improve quality of life. (35)
Diet and physical activity guidance can dramatically influence the course of PCOS in women and should be implemented in the care of all women with this condition. (6) The goal of diet and physical activity interventions, according to some authors, is weight loss, which can be difficult to achieve in PCOS. (42-44) In addition to reducing metabolic sequelae of PCOS, weight loss will also promote fertility (22) and quality of life. (15) Other authors contend that women with PCOS achieve the benefits of physical activity and healthy eating regardless of BMI and that metabolic risk profiles and quality of life should be the primary goals of lifestyle management. (45,46) Regardless of the goals, the interventions should be medically monitored, (24) and this follow-up seems more important than the composition of the recommended diet. (47)
The use of pharmacotherapeutics in PCOS is largely informed by women’s symptomatology and goals of care. The phenotypic diversity of PCOS brings different problems and priorities for individual patients, so there is no single stepwise treatment regimen. As many goals of care can be met with pharmacotherapeutics, Badawy (41) offers a current overview of pharmacological strategies. In what follows, we summarize some general recommendations. All oligomenorrhoeic or amenorrhoeic women should receive some form of treatment to prevent endometrial hyperplasia, which is a consequence of chronic exposure to unopposed estrogen that results from oligo– and anovulation. For women in which lifestyle management or insulin sensitizers do not induce regular cycles, treatment can take the forms of cyclic progesterone to induce regular bleeds, or menstrual suppression with hormonal contraceptives. Women who are not receiving continuous menstrual suppression should have an induced bleed or menses at least every three months. Metformin (Glucophage) and statins can be used in PCOS to address the metabolic problems related to insulin resistance, including hypercholesterolemia. Spironolactone (Aldactone), flutamide (Euflex), and finasteride (Propecia) are various effective antiandrogens. Oral contraceptives are commonly used to induce regular bleeds (thus preventing endometrial hyperplasia and cancer) and to treat hirsutism and acne in women who also seek contraception. Many of these pharmacologic interventions that are useful for women with PCOS can be implemented in primary care, but more specialized treatments are appropriate for consultant practice in dermatology, reproductive endocrinology, or other areas of medicine.
The first step in meeting some of the goals of care is regular laboratory screening. Though some suggest adhering to T2DM screening guidelines and offering women fasting blood glucose testing, (48) many other authors suggest this test is not sensitive enough in the PCOS population and routine, even annual, screening for IGT and T2DM with oral glucose tolerance testing is warranted in all patients from adolescence through post-menopausal life. (20- 22,43,49) However, this is not yet the standard of care for women with PCOS. (22) Regular lipid profiles are recommended for all women with PCOS to assess those components of METS and overall cardiovascular risk. (29)
Women with PCOS experience significant health risks and should have access to early diagnosis and management to prevent metabolic and psychosocial sequelae. Healthcare providers should maintain a high index of suspicion for the disease and offer risk-appropriate management to women presenting with signs of PCOS. Care by specialist physicians is often indicated for particular complications, but many important aspects of management are well-suited to a comprehensive approach in primary care.
1. Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006 Aug;30(1):19-26.
2. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: Involvement of genetic and environmental factors. Int J Androl. 2006 Feb;29(1):278-285.
3. Pasquali R, Gambineri A. Polycystic ovary syndrome: A multifaceted disease from adolescence to adult age. Ann N Y Acad Sci. 2006 Dec;1092:158-174.
4. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010 Feb;25(2):544-551.
5. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, EscobarMorreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab. 2010 May;95(5):2038-2049.
6. The Rotterdam ESHRA/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25.
7. Geisthövel F, Rabe T. The ESHRE/ASRM consensus on polycystic ovary syndrome(PCOS)-an extended critical analysis. Reproductive Biomedicine Online 2007:14(4):522-535.
8. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, EscobarMorreale HF, Futterweit W, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril. 2009 Feb;91(2):456-488.
9. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril. 2010 Nov;94(6):2197-2201.
10. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligoamenorrhoea but normal androgen levels: Implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007 Apr;66(4):513-517.
11. Lujan ME, Chizen DR, Pierson RA. Diagnostic criteria for polycystic ovary syndrome: Pitfalls and controversies. J Obstet Gynaecol Can. 2008 Aug;30(8):671-679.
12. Diamanti-Kandarakis E. Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008 Jan 30;10:e3.
13. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol. 2007;8(4):201-219.
14. Wright CE, Zborowski JV, Talbott EO, McHugh-Pemu K, Youk A. Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. Int J of Obes Relat Metab Disord. 2004 Aug;28(8):1026-1032.
15. Coffey S, Bano G, Mason HD. Health-related quality of life in women with polycystic ovary syndrome: A comparison with the general population using the polycystic ovary syndrome questionnaire (PCOSQ) and the short form-36 (SF-36). Gynecol Endocrinol. 2006 Feb;22(2):80-86.
16. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65(2):137-145.
17. Cosar E, Uçok K, Akgün L, Köken G, Sahin FK, Arioz DT, et al. Body fat composition and distribution in women with polycystic ovary syndrome. Gynecol Endocrinol. 2008 Aug;24(8):428-432.
18. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes (Lond). 2007 Nov;31 Suppl 2:S8.
19. Takeuchi T, Tsutsumi O, Taketani Y. Abnormal response of insulin to glucose loading and assessment of insulin resistance in non-obese patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008 Jul;24(7):385-391.
20. Vrbikova J, Dvorakova K, Grimmichova T, Hill M, Stanicka S, Cibula D, et al. Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome. Clin Chem Lab Med. 2007;45(5):639- 644.
21. Bhattacharya SM. Abnormal glucose tolerance in polycystic ovary syndrome. J Obstet Gynaecol Res. 2008 Apr;34(2):228-232.
22. Balen AH, Anderson RA. Impact of obesity on female reproductive health: British fertility society, policy and practice guidelines. Hum Fertil (Camb). 2007 Dec;10(4):195-206.
23. Talbott EO, Zborowski JV, Rager JR, Kip KE, Xu X, Orchard TJ. Polycystic ovarian syndrome (PCOS): A significant contributor to the overall burden of type 2 diabetes in women. J Womens Health. 2007 Mar;16(2):191-197.
24. Cobin RH, Futterweit W, Nestler JE, Reaven GM, Jellinger PS, Handelsman Y, et al. American association of clinical endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract. 2005 Mar-Apr;11(2):125-134.
25. Ramos RG, Olden K. The prevalence of metabolic syndrome among US women of childbearing age. Am J Public Health. 2008 Jun;98(6):1122-1127.
26. Bhattacharya SM. Metabolic syndrome in females with polycystic ovary syndrome and international diabetes federation criteria. J Obstet Gynaecol Res. 2008 Feb;34(1):62-66.
27. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):48-53.
28. Diamanti-Kandarakis E, Economou F. Stress in women: Metabolic syndrome and polycystic ovary syndrome. Ann N Y Acad Sci. 2006 Nov;1083:54-62.
29. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: Systematic review and meta-analysis. Fertil Steril. 2011 Mar 1;95(3):1073,1079.e11.
30. Mason H, Colao A, Blume-Peytavi U, Rice S, Qureshi A, Pellatt L, et al. Polycystic ovary syndrome (PCOS) trilogy: A translational and clinical review. Clin Endocrinol (Oxf). 2008 Dec;69(6):831- 844.
31. Cocksedge KA, Li TC, Saravelos SH, Metwally M. A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage. Reprod Biomed Online. 2008 Jul;17(1):151-160.
32. Yang CJ, Stone P, Stewart AW. The epidemiology of recurrent miscarriage: A descriptive study of 1214 prepregnant women with recurrent miscarriage. Aust NZ J Obstet Gynaecol. 2006 Aug;46(4):316-322.
33. Bower JK, Schreiner PJ, Sternfeld B, Lewis CE. Black-white differences in hysterectomy prevalence: The CARDIA study… coronary artery risk development in young adults. Am J Public Health. 2009 Feb;99(2):300-307.
34. Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Polycystic ovary syndrome and gynecological cancers: Is there a link? Gynecol Endocrinol. 2005 Apr;20(4):200-208.
35. Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: Body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf). 2007 Mar;66(3):373-379.
36. Deeks AA, Gibson-Helm ME, Teede HJ. Anxiety and depression in polycystic ovary syndrome: A comprehensive investigation. Fertil Steril. 2010 May 1;93(7):2421-2423.
37. Bhattacharya SM, Jha A. Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertil Steril. 2010 Jun;94(1):357-359.
38. Morgan J, Scholtz S, Lacey H, Conway G. The prevalence of eating disorders in women with facial hirsutism: An epidemiological cohort study. Int J Eat Disord. 2008 Jul;41(5):427-431.
39. Naessén S, Carlström K, Garoff L, Glant R, Hirschberg AL. Polycystic ovary syndrome in bulimic women–an evaluation based on the new diagnostic criteria. Gynecol Endocrinol. 2006 Jul;22(7):388-394.
40. Trent M, Austin SB, Rich M, Gordon CM. Overweight status of adolescent girls with polycystic ovary syndrome: Body mass index as mediator of quality of life. Ambulatory Pediatr. 2005 MarApr;5(2):107-111.
41. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011 Feb 8;3:25-35.
42. Mastorakos G, Lambrinoudaki I, Creatsas G. Polycystic ovary syndrome in adolescents: Current and future treatment options. Paediatr Drugs. 2006;8(5):311-318. 43. Blank SK, Helm KD, McCartney CR, Marshall JC. Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci. 2008;1135:76- 84. 44. Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: A practical guide. Drugs. 2006; 66(7):903-912. 45. Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab. 2006 Aug;31(4):384-391.
46. Liao LM, Nesic J, Chadwick PM, Brooke-Wavell K, Prelevic GM. Exercise and body image distress in overweight and obese women with polycystic ovary syndrome: A pilot investigation. Gynecol Endocrinol. 2008 Oct;24(10):555-561.
47. Moran LJ, Brinkworth G, Noakes M, Norman RJ. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online. 2006 May;12(5):569-578.
48. Lau D. Screening for diabetes in women with polycystic ovary syndrome. CMAJ. 2007 Mar 27;176(7):951-952.
49. Gagnon C, Baillargeon JP. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ. 2007 Mar 27;176(7):933-938.